

Disclosure of acquisition of treasury shares

Fagron discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Fagron today announces that during the period from 16 February 2015 to 20 February 2015, it acquired 16,500 treasury shares on Euronext Brussels.

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
16 February 2015	-	-	-	-	-
17 February 2015	-	-	-	-	-
18 February 2015	-	-	-	-	-
19 February 2015	-	-	-	-	-
20 February 2015	16,500	€ 32.8952	€ 32.75	€ 33.00	€ 542,771

Prior to the transactions, Fagron held 597,479 treasury shares. As a result of the acquisition of 16,500 treasury shares, Fagron now holds 613,979 treasury shares, representing 1.95% of the total number of shares outstanding.

Fagron will publish a weekly update every Monday provided that shares were bought back in the preceding week.



Fagron profile

Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Fagron offers Fagron Compounding Essentials, Fagron Trademarks and Fagron Compounding Services to pharmacies and hospital pharmacies in 30 countries. Pharmaceutical compounding is an essential part of pharmaceutical care that enables pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron's own R&D organisation consists of more than 300 pharmacists who are working continually on developing new formulations to treat an increasing number of patients with customised compounded medication.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

For further information

Marieke Palstra
Global Investor Relations Director
Tel. +31 88 33 11 213
marieke.palstra@fagron.com
investors.fagron.com

In the event of any discrepancy between the Dutch translation and the original English version of this press release, the latter shall prevail.

